Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia Clin Transl Sci. 2024;17:e70074. Vaddady P, Glatard A, Smania G, Nakayama S, Inoue H, Kurumaddali A, Abutarif M, Zheng M. JournalOncologyPharmacometricsRegulatory interactions Pharmetheus Affiliates Senior Consultant & Team Leader Giovanni Smania See bio Senior Consultant Anaïs Glatard See bio Associate Quality Control and Medical Writer Christina Pentafragka See bio Connected publication Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia